Skip to main content

Table 3 Association of fatty liver disease, metabolic dysfunction and their interaction with systemic atherosclerosis

From: Association of metabolic dysfunction-associated fatty liver disease with systemic atherosclerosis: a community-based cross-sectional study

Factor

N

Extent of atherosclerotic plaquesa

Extent of atherosclerotic stenosisa

PolyVDb

Adj. cOR (95% CI)

P value

Adj. cOR (95% CI)

P value

Adj. OR (95% CI)

P value

No FLD/No MD

474

Ref.

 

Ref.

 

Ref.

 

No FLD/MD

1089

1.82 (1.48–2.24)

 < 0.001

1.88 (1.46–2.42)

 < 0.001

2.24 (1.46–3.43)

 < 0.001

FLD/No MD

20

4.47 (1.78–11.21)

0.001

4.30 (1.80–10.24)

0.001

5.57 (1.65–18.76)

0.006

FLD/MD

1464

3.28 (2.67–4.02)

 < 0.001

2.34 (1.84–2.98)

 < 0.001

2.87 (1.91–4.33)

 < 0.001

P for interaction

  

0.055

 

0.006

 

0.02

  1. MD, metabolic dysfunction; FLD, fatty liver disease; PolyVD, polyvascular disease; cOR, common odds ratio; OR, odds ratio; CI, confidence intervals; Adj., adjusted; Ref., reference
  2. All models were adjusted for sex, age, marital status, education, income, current smoking, current drinking, sleep time, sedentary time, family history of ASCVD, eGFR, lipid-lowering medication, antiplatelet medication, and anticoagulants medication
  3. aThe extent of atherosclerotic plaques and stenosis was defined according to the number of 8 vascular sites affected and was divided into four groups, including 0, 1, 2–3, and 4–8 vascular sites. Adjusted cOR and 95% CI were calculated by the ordinary logistic regression model
  4. bPolyVD was defined as the presence of atherosclerotic stenosis in at least two vascular sites. Adjusted OR and 95% CI were calculated by the binary logistic regression model
Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840